Nail alterations as a surrogate marker for the efficacy
of low-dose metronomic chemotherapy

KAYOKO KIBATA, TAKESHI TAMAKI, NORIKO INAGAKI, MAKOTO OGATA,
TOSHIKI SHIMIZU and SHOSAKU NOMURA

First Department of Internal Medicine, Kansai Medical University, Moriguchi, Osaka 570-8506, Japan

Received November 25, 2012; Accepted January 31, 2013

DOI: 10.3892/ol.2013.1178

Abstract. Docetaxel is a well-known causative agent of nail alterations. The aim of this study was to reveal the impact of nail alterations associated with low-dose metronomic (LDM) docetaxel chemotherapy on the survival of non-small cell lung cancer (NSCLC) patients. Clinical information, survival data and nail alterations in patients treated with LDM docetaxel chemotherapy (docetaxel 15 mg/m² per week) were retrospectively reviewed. Forty-nine patients were included in this study. Various nail alterations were observed in 17 of the 49 patients (34.7%). Onycholysis and subungual hyperkeratosis were observed in 22.4% and 10.2% of patients, respectively. The number of docetaxel administration cycles was correlated with the incidence and severity of nail alterations. Univariate and multivariate analysis clearly demonstrated that the occurrence of nail alterations was an independent favorable prognostic factor for overall survival. Nail alterations associated with treatment may act as a surrogate marker for the efficacy of low-dose metronomic docetaxel chemotherapy.

Introduction

Systemic antitumor chemotherapy induces treatment-associated adverse effects in various organs, including the skin and nails (1). To date, skin and nail alterations have attracted a great deal of interest due to their potential as surrogate markers for molecular-targeted therapies, in particular epidermal growth factor receptor (EGFR)-targeted treatment (2). A close correlation has been observed between the severity of skin/nail alterations, treatment efficacy and the survival benefits of EGFR-targeted treatment (3).

Data collection. The medical records of all NSCLC patients who were treated between January 1999 and December 2010 in Kansai Medical University Takii Hospital (Moriguchi-City, Japan) were retrospectively reviewed after Institutional Review Board approval. Patients were included in this study if they had advanced stage (III or IV) or relapsed NSCLC that was treated with LDM chemotherapy using docetaxel. A clinical stage was assigned according to the sixth edition of the TNM Classification for Lung Cancer (14). Data with regard to gender, age, clinical stage, histological typing of cancer, Eastern Cooperative Oncology Group (ECOG) performance status (PS), progression-free survival (PFS) and overall survival (OS) were obtained retrospectively from the medical records. Adverse effects on the finger- and toenails observed during the treatment period were also ascertained retrospectively from the medical records and photographs of the nails of patients were retrieved with informed consent. All patients provided written informed consent before undergoing chemotherapy. The study was carried out according to the

Key words: docetaxel, nail alterations, onycholysis, subungual hyperkeratosis, metronomic chemotherapy, non-small cell lung cancer
Declaration of Helsinki and was approved by the Institutional Ethics Review Board (Subcommittee for the Epidemiologic Study, Institutional Review Board of Kansai Medical University).

Treatment. Docetaxel (15 mg/m²) diluted with 250 ml of a 5% glucose solution was administered intravenously over 60 min each week. The treatment was administered on a weekly basis without any intervals. To prevent a hypersensitive reaction, 2 mg of dexamethasone or H1-blocker was administered as a premedication to all patients. The treatment was repeated, with the exception of cases where disease progression was observed. Responses were evaluated using a chest CT every month during the treatment period. Administration of docetaxel was bypassed if the patient experienced unacceptable toxicity (e.g., grade 3 or worse hematological/non-hematological toxicity, excluding appetite loss, constipation and nausea/vomiting). Patients who refused to continue this regimen and those who showed a decline in performance status (PS; PS 4) were also allowed to avoid LDM chemotherapy.

Statistical analysis. Statistically significant differences between groups were compared using Student’s t-test, a Chi-square test or Fisher’s exact test. Spearman’s correlation coefficients (two-tailed) were used to evaluate whether the number of docetaxel administration cycles correlated with the level of nail alterations. Logistic regression was used to test the univariate dose-response correlation and multivariate associations with the development of nail alterations. Variables were considered for the multivariate models if their univariate P-value was <0.25. Overall survival (OS) was defined as the time from the start of LDM chemotherapy to the time of death from any cause or to the date the patient was last known to be alive. Progression-free survival was defined as the time between the start of LDM treatment and disease progression, death or last known follow-up. Objective tumor responses to chemotherapy were evaluated using the Response Evaluation Criteria in Solid Tumors version 1.0 (15). The objective response rate (ORR) was defined as the number of patients showing a complete response (CR) and a partial response (PR) relative to the total number of patients evaluated. The disease control rate (DCR) was defined as the number of patients showing CR, PR and stable disease (SD) relative to the total number of patients evaluated. The minimum time interval between the 2 measurements required for the determination of SD was 6 weeks. The 95% confidence intervals (95% CI) for the ORR and DCR were calculated using binomial distribution. Univariate and multivariate analysis of PFS and OS were performed using the Kaplan-Meier product-limit method using the log-rank test and the Cox proportional hazards model, respectively. The 95% CI for the survival rate was calculated using Greenwood’s method. To calculate the 95% CI of the median survival time (MST), the Brookmeyer and Crowley method was used.

All statistical analysis was conducted using the JMP (version 9.0.2) software program for Windows (SAS Institute Inc., Cary, NC, USA). All statistical tests were two-sided and P<0.05 was considered to indicate a statistically significant difference.

Results

Patient characteristics. Between January 1999 and December 2010, 49 patients with NSCLC who met the eligibility criteria were enrolled in this study. Patient characteristics are summarized in Table I. All patients were Japanese and the median age was 69 years (range, 32-85 years). Ten patients were female and 39 were male. Adenocarcinoma and squamous cell carcinoma were present in 30 and 19 patients, respectively. Twenty-two patients had stage III disease, whereas 27 patients had stage IV disease. The ECOG PS was 0 and 1 in 21 and 28 patients, respectively. Twenty-seven patients had received at least 1 regimen of cytotoxic chemotherapy prior to this LDM regimen, but the remaining 22 patients had never been treated. The median number of cycles administered to the 49 patients was 16 (range, 2-60). Eleven patients received at least 1 further chemotherapy regimen, including EGFR-tyrosine kinase inhibitor, following this LDM regimen.

Nail alterations. No nail alterations were observed at the beginning of this LDM regimen. In the present study, various nail alterations were observed in 17 out of 49 patients (34.7%) during and after treatment. As previously described, docetaxel is known to induce various nail alterations. Examples include nail discoloration (including subungual hemorrhage), onycholysis, subungual hyperkeratosis, aseptic subungual abscess, loss of transverse line and Beau's line (1). In this study, dark nail discoloration, onycholysis, subungual hyperkeratosis and aseptic subungual abscess were observed (Fig. 1), but Beau's line and loss of transverse line were not. The metronomic schedule, as opposed to the conventional schedule of the maximum tolerated dose every three weeks, may be responsible for the observed spectrum of nail alterations. Nail alterations developed 8 weeks from the first administration of docetaxel. A spontaneous remission of nail alterations was observed after the withdrawal of LDM docetaxel treatment. Recovery of nail discoloration and reattachment of the nail to the nail bed was observed ~8 weeks after the last docetaxel administration. These findings indicate that nail alterations due to the LDM docetaxel treatment are reversible.

The nail alterations appeared to develop in a step-wise manner. Nail discoloration occurred first, followed by onycholysis. Finally, subungual hyperkeratosis and aseptic pus were observed. Since the most recent version of the common toxicity criteria (CTCAE v.4.03) for nail alterations is abstract and has only a few grades, a novel grading scale for nail alterations was developed in this study (16). Nail alterations were classified into 4 subsets according to severity (Table II): No evident nail alterations (level 0, 32 cases), nail discoloration only (level 1, 6 cases), nail discoloration with onycholysis (level 2, 6 cases) and nail discoloration and onycholysis with subungual hyperkeratosis (level 3, 5 cases). Subsequently, we attempted to determine whether the cycle number of docetaxel administration correlated with a particular level of nail alterations. Spearman’s correlation coefficients (2-tailed) were used to evaluate the correlation between cycle number and the level of nail alterations. Statistical analysis revealed that a larger number of docetaxel administrations correlated with a higher degree of nail alterations (Spearman’s ρ=0.6409, P<0.0001; Fig. 2).
The risk factors for the development of nail alterations were assessed. Univariate analysis showed that the number of treatment cycles (P<0.0001), female gender (P=0.0212), PS 0 (P=0.0351) and treatment-associated pleural effusion (P=0.0058) were statistically significant risk factors for the development of nail alterations (Table I). However, multiple logistic regression analysis indicated that the number of treatment cycles [P=0.0005; odds ratio (OR), 1.148/cycle], PS 0 (P=0.0195; OR, 8.907) and treatment-associated pleural effusion (P=0.0492, OR, 10.138) were independent risk factors for the development of nail alterations (Table III).

Effect of nail alterations on survival. The effect of nail alterations in this LDM regimen (Table IV) on survival was evaluated. The MST for the patients with and without nail alterations was 30.6 and 6.7 months, respectively. Univariate

Table I. Patient and disease characteristics.

| Characteristics                  | Total patients (n=49) | Patients with nail alterations (n=17) | Patients without nail alterations (n=32) | P-value |
|----------------------------------|-----------------------|--------------------------------------|----------------------------------------|---------|
| Gender                           |                       |                                      |                                        | 0.0212* |
| Male                             | 39                    | 10                                   | 29                                     |         |
| Female                           | 10                    | 7                                    | 3                                      |         |
| Age (years)                      |                       |                                      |                                        | 0.8457  |
| Median                           | 69                    | 71                                   | 68.5                                   |         |
| Range                            | 32-85                 | 49-85                                | 32-83                                  |         |
| ECOG PS                          |                       |                                      |                                        | 0.0351* |
| 0                                | 21                    | 11                                   | 10                                     |         |
| 1                                | 28                    | 6                                    | 22                                     |         |
| Histology (cytology)             |                       |                                      |                                        | 0.1347  |
| Ad                               | 30                    | 13                                   | 17                                     |         |
| Sq                               | 19                    | 4                                    | 15                                     |         |
| Disease stage                    |                       |                                      |                                        | 1.0000  |
| III                              | 22                    | 8                                    | 14                                     |         |
| IV                               | 27                    | 9                                    | 18                                     |         |
| Prior systemic therapies         |                       |                                      |                                        | 0.5480  |
| 0 regimen                        | 22                    | 8                                    | 19                                     |         |
| ≥1 regimen                       | 27                    | 9                                    | 13                                     |         |
| Treatment cycles                 | 1,003                 | 557                                  | 446                                    | <0.0001*|
| Median                           | 16                    | 31                                   | 12                                     |         |
| Range                            | 2-60                  | 9-60                                 | 2-48                                   |         |
| DTX dose (mg/body/week)          |                       |                                      |                                        | 0.5073  |
| Median                           | 20                    | 20                                   | 20.5                                   |         |
| Range                            | 17-28                 | 17-27                                | 18-28                                  |         |
| Post-systemic therapies          |                       |                                      |                                        | 0.1562  |
| 0 regimen                        | 38                    | 11                                   | 27                                     |         |
| ≥1 regimen                       | 11                    | 6                                    | 5                                      |         |
| Pleural effusion                 |                       |                                      |                                        | 0.0058* |
| Observed                         | 30                    | 15                                   | 15                                     |         |
| Not observed                     | 19                    | 2                                    | 17                                     |         |
| ORR (%)                          | 8.2                   | 17.6                                 | 3.1                                    | 0.1139  |
| DCR (%)                          | 53.1                  | 70.6                                 | 43.8                                   | 0.1317  |

*P<0.05. ECOG, Eastern Cooperative Oncology Group; PS, performance status; Ad, adenocarcinoma; Sq, squamous cell carcinoma; DTX, docetaxel; ORR, overall response rate; DCR, disease control rate.

Table II. Summary of nail alterations observed (n=49).

| Level | Definition                              | Patients, n (%) |
|-------|-----------------------------------------|-----------------|
| 0     | No evident nail alterations             | 32 (65.3)       |
| 1     | Discoloration                           | 6 (12.2)        |
| 2     | Level 1 + onycholysis                   | 6 (12.2)        |
| 3     | Level 2 + subungual hyperkeratosis      | 5 (10.2)        |
| 1-3   | Total nail alterations                  | 17 (34.7)       |

Risk factors. The risk factors for the development of nail alterations were assessed. Univariate analysis showed that the number of treatment cycles (P<0.0001), female gender (P=0.0212), PS 0 (P=0.0351) and treatment-associated pleural effusion (P=0.0058) were statistically significant risk factors for the development of nail alterations (Table I). However, multiple logistic regression analysis indicated that the number of treatment cycles [P=0.0005; odds ratio (OR), 1.148/cycle], PS 0 (P=0.0195; OR, 8.907) and treatment-associated pleural effusion (P=0.0492, OR, 10.138) were independent risk factors for the development of nail alterations (Table III).
analysis indicated that the patients with nail alterations showed significantly longer survival than those without nail alterations ($P=0.0006$; Fig. 3A). Additionally, female gender ($P=0.0154$), age <70 years ($P=0.0108$), the presence of adenocarcinoma ($P=0.0049$), prior chemotherapy ($P=0.0099$), PS 0 ($P=0.0400$) and treatment-associated pleural effusion ($P=0.0245$) were significant prognostic factors for OS (Fig. 3B). By contrast, multivariate analysis revealed that the development of nail alterations [hazard ratio (HR), 0.2138; 95% CI, 0.0809-0.5515; $P=0.0014$] and prior systemic chemotherapy (HR, 0.3485; 95% CI, 0.1613-0.7459; $P=0.0068$) were independent favorable prognostic factors for OS. The patients with nail alterations also showed a significantly longer PFS than those without nail alterations ($P=0.0037$; Fig. 3C).

**Discussion**

LDM chemotherapy targets the tumor vascular system (7-9). This suggests that the deterioration of constitutive remodeling of the microvascular network surrounding the tumor tissue may lead to a decrease in tumor burden. However, this type

---

Table III. Multiple logistic regression analysis of the clinical parameters associated with nail alteration.

| Clinical parameters     | OR (95% CI)     | P-value |
|-------------------------|-----------------|---------|
| Number of cycles (/cycle) | 1.148 (1.053-1.296) | 0.0005<sup>a</sup> |
| Female vs. male          | 8.736 (0.986-128.278) | 0.0515 |
| PS 0 vs. PS 1            | 8.907 (1.393-97.050) | 0.0195<sup>a</sup> |
| Sq vs. Ad                | 3.450 (0.381-49.322) | 0.2803 |
| Pleural effusion vs. absent | 10.138 (1.007-253.901) | 0.0492<sup>a</sup> |

<sup>a</sup>P<0.05. OR, odds ratio; 95% CI, 95% confidence interval; Sq, squamous cell carcinoma; Ad, adenocarcinoma; PS, performance status. $R^2=0.5101$, $P<0.0001$. 

---

Figure 1. Representative images of nail alterations. (A) Dark pigmentation of fingernails (level 1); (B) onycholysis of fingernails (level 2); (C and D) subungual hyperkeratosis in fingernails (level 3).

Figure 2. Correlation between the number of docetaxel administration cycles and the level of nail alterations. Scattergram with 95% probability ellipse showing significant correlation between the number of cycles and the level of nail alterations ($R=0.6627$, $\rho=0.6045$, $P<0.0001$).

Figure 3. Kaplan-Meier survival curves for the patients who received low-dose metronomic docetaxel chemotherapy. Kaplan-Meier survival curves of overall survival (OS) for the patients classified according to (A) nail alterations and (B) pleural effusion. (C) Kaplan-Meier survival curves of progression-free survival (PFS) for the patients, classified according to nail alterations. MST, median survival time.
of chemotherapy may also damage non-tumor-associated microvascular networks in normal tissue, as tumor vessels are derived from the normal vascular system and composed of genetically normal endothelial cells. Microvessels in the nail bed or pleural architecture are also likely to be affected. Consequently, nail alterations or capillary leakage resulting in pleural effusion may be induced. This may explain the close correlation observed in this study between nail alterations and pleural effusion. If a common pathogenic procedure is introduced by LDM chemotherapy, one might become a surrogate marker for the other. In this study, we showed that the development of nail alterations during LDM docetaxel chemotherapy was an independent favorable prognostic factor for OS. Therefore, nail alterations observed during treatment may be a potential surrogate marker for the efficacy of LDM docetaxel chemotherapy.

LDM chemotherapy has been shown to induce nail alterations more frequently than other treatments, particularly onycholysis, which is characterized by nail plate detachment from the nail bed and often results from subungual hemorrhage. In conventional chemotherapy with docetaxel (100 mg/m² every 3 weeks), onycholysis was identified in 19% of patients (17). By contrast, onycholysis was observed in 12 out of 49 patients (24.5%) treated with a metronomic low dose of docetaxel (15 mg/m² every week). Onycholysis and subungual hyperkeratosis have also been observed in patients with psoriasis, onychomycosis and certain autoimmune diseases, in addition to malignant tumor patients receiving chemotherapy (18-20). Although their pathological etiology remains to be elucidated, a number of studies support the possibility of a neurological involvement in the pathogenesis of these nail alterations. It has been reported that onycholysis or subungual hyperkeratosis does not extend to the nails of the paretic limb due to cerebrovascular events or metastatic brain tumors (21-24). These findings suggest that the neurological network is likely to play an essential transmissive role in the pathogenesis of nail alterations.

Another common pathogenic process for nail alterations may be capillary leakage, an alternative antitumor effect due to LDM docetaxel chemotherapy. A few studies have indicated that certain neuropeptides are able to induce an increase in vascular permeability and consequent plasma leakage (25,26). Moreover, docetaxel enhances microtubule assembly, leading to an interference of axonal flow and an impediment to the innervation of the microvascular network (27,28). According to these findings, treatment-associated adverse neurological effects may also be a favorable predictive factor for LDM docetaxel chemotherapy. However, no survival benefit was able to be associated with neurotoxicities in this study, as no neurological events occurred in our study population. Additionally, no significant results have been reported to support the effect of neurotoxicities associated with taxane-based chemotherapy on survival. A possible explanation for this is that neurosensory and neurovascular networks might be independently affected by taxanes. A recent study showed that there was no association between intraepidermal nerve fiber density and neurological symptoms during chemotherapy with neurotoxic agents (29).

Although we have clearly demonstrated the favorable impact of treatment-associated nail alterations on survival and shown for the first time that these nail alterations act as a surrogate marker for the efficacy of LDM docetaxel chemotherapy, this study had a number of limitations. The study population was small and heterogeneous, containing previously untreated and relapsed patients. In addition, the arbitrary nail alteration severity index defined in this study was qualitative, not quantitative.

The quality of life for patients undergoing antineoplastic treatment is becoming a more important issue. The quality and length of life for an individual should not be considered in mutually exclusive terms. Numerous physicians have pointed out that nail alterations are not a life-threatening adverse effect and are therefore not enough of a reason to abstain from chemotherapy (13). In the present study, we have demonstrated for the first time that nail alterations may act as a surrogate marker for the efficacy of LDM chemotherapy. Our preliminary findings provide a basis for further investigation into LDM chemotherapy.

Table IV. Univariate and multivariate analysis for OS.

| Covariate                                | Univariate analysis | Multivariate analysis |
|------------------------------------------|---------------------|-----------------------|
|                                          | MST (Mo)            | P-value               | HR (95% CI)     | P-value               |
| Female vs. male                          | 36.4 vs. 8.5        | 0.0154a               | 1.0949 (0.3495-2.9692) | 0.8673               |
| Age <70 vs. ≥70 years                    | 16.4 vs. 7.5        | 0.0108a               | 0.6855 (0.3262-1.4259) | 0.3107               |
| Ad vs. Sq                                | 16.4 vs. 7.2        | 0.0049a               | 0.6409 (0.3146-1.3271) | 0.2266               |
| Relapsed vs. naïve                       | 16.4 vs. 7.6        | 0.0099a               | 0.3485 (0.1613-0.7459) | 0.0068a              |
| PS 0 vs. PS 1                            | 25.7 vs. 7.6        | 0.0400a               | 0.9548 (0.4395-2.0791) | 0.9065               |
| Stage III vs. IV                         | 9.0 vs. 9.8         | 0.3758                | 0.7655 (0.3792-1.5090) | 0.4424               |
| Nail alterations (observed vs. absent)   | 30.6 vs. 6.7        | 0.0006a               | 0.2138 (0.0809-0.5515) | 0.0014a              |
| Pleural effusion (observed vs. absent)   | 11.6 vs. 7.0        | 0.0245a               | 0.5613 (0.2908-1.0860) | 0.0858               |

*P<0.05. OS, overall survival; MST, median survival time; Mo, months; HR, hazard ratio; 95% CI, 95% confidence interval; Ad, adenocarcinoma; Sq, squamous cell carcinoma; PS, performance status.
References

1. Gilpar P, Hain A and Peerboom VM: Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract 15: 143-155, 2009.
2. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP and Le Chevalier T: Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6: 491-500, 2005.
3. Tiseo M, Rossi G, Capellletti M, Sartori G, Spirtielli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G and Ardizzoni A: Predictors of gelfiitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer 67: 355-360, 2010.
4. Gourn M, Habermann CR, Anige M, Thiom I, Schuch G, Andritzky B, Brandl S, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C and Laack E: A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie 31: 185-189, 2008.
5. Young SD, Lafrenie RM and Clemons MJ: Phase ii trial of a metronomic schedule of docetaxel and capetabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer. Curr Oncol 19: 75-83, 2012.
6. Ladoire S, Eymard JC, Zanetta S, Mignot G, Martin E, Kermarrec I, Murey E, Michel F, Cormier L and Gheringhelli F: Metronomic oral cyclophosphamide preindolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. Anticancer Res 30: 4317-4323, 2010.
7. Browder T, Butterfield CE, Kräling BM, Marshall B, O'Reilly MS and Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2000.
8. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y and Kerbel RS: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63: 4342-4346, 2003.
9. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G and Kerbel RS: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62: 2731-2735, 2002.
10. Yokoi T, Tamaki T, Shimizu T and Nomura S: A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer. Lung Cancer: Targets and Therapy 3: 15-20, 2012.
11. Hong J, Park SH, Choi SJ, Lee SH, Lee KC, Lee JI, Kyung SY, An CH, Lee SP, Park JW, Jeong SH, Nam E, Bang SM, Cho EK, Shin DB and Lee JH: Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 37: 424-427, 2008.
12. Roh MR, Cho JY and Lew W: Docetaxel-induced onycholysis: the role of subungal hemorrhage and suppuration. Yonsei Med J 48: 124-126, 2007.
13. Correia O, Azevedo C, Pinto Ferreira E, Braga Cruz F and Polónia J: Nail changes secondary to docetaxel (Taxotere). Dermatology 198: 288-290, 1999.
14. Sohn L and Wittekind CH (eds): TNM Classification of Malignant Tumours. 6th edition. Wiley-Liss, New York, pp99-103, 2002.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
16. National Cancer Institute (NCI): Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, 28 May 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed October 9, 2012.
17. ten Bokkel Huink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alaki M, Bayssas M and Kaye SB: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5: 527-532, 1994.
18. Grover C, Reddy BS and Uma Chaturvedi K: Diagnosis of nail psoriasis: importance of biopsy and histopathology. Br J Dermatol 153: 1153-1158, 2005.
19. Scher RK, Tavakkol A, Sigurjonsrson B, Hay RJ, Joseph WS, Tosti A, Fleckman P, Ghannoum M, Armstrong DG, Markinson BC and Elewski BE: Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 56: 939-944, 2007.
20. Richert B, André J, Burgquignon R and de la Brassinne M: Hyperkeratotic nail discoid lupus erythematosus evolving towards systemic lupus erythematosus: therapeutic difficulties. J Eur Acad Dermatol Venereol 18: 728-730, 2004.
21. Stevenson R and El-Modir A: Unilateral onycholysis in a patient taking erlotinib (Tarceva). BMJ Case Rep 2011: doi: 10.1136/ bcr.04.2011.4157.
22. Truchuelo M, Vano-Galvan S, Pérez B, Muñoz-Zato E and Jaén P: Unilateral taxane-induced onychopathy in a patient with a brain metastasis. Dermatol Online J 15: 7, 2009.
23. Badger J, Banerjee AK and McFadden J: Unilateral subungal hyperkeratosis following a cerebrovascular incident in a patient with piorrhea. Clin Exp Dermatol 17: 454-455, 1992.
24. Wasner G, Hilpert F, Schattschneider J, Binder A, Pfister J and Baron R: Docetaxel-induced nail changes - a neurogenic mechanism: a case report. J Neurooncol 58: 167-174, 2002.
25. Fujiwara H, Hashikawa-Hobara N, Wake Y, Takatori S, Goda M, Higuchi H, Zamami Y, Tansugcharit P and Kawasaki H: Neurogenic vascular responses in male mouse mesenteric vascular beds. J Pharmacol Sci 119: 260-270, 2012.
26. Brain SD and Williams TJ: Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol 86: 855-860, 1985.
27. Fazio R, Quattrini A, Bolognesi A, Bordogna G, Villa E, Previtali S, Canal N and Nemni R: Docetaxel neuropathy: a distal axonopathy. Acta Neuropathol 98: 651-653, 1999.
28. New PZ, Jackson CE, Rinaldi D, Burris H and Barohn RJ: Taxotere neuropathy: a taxane-induced distal axonopathy. Acta Neuropathol 98: 651-653, 1999.
29. Previtali S, Canal N and Nemni R: Docetaxel neuropathy: a neurogenic mechanism: a case report. J Neurooncol 58: 167-174, 2002.
30. Fujiwara H, Hashikawa-Hobara N, Wake Y, Takatori S, Goda M, Higuchi H, Zamami Y, Tansugcharit P and Kawasaki H: Neurogenic vascular responses in male mouse mesenteric vascular beds. J Pharmacol Sci 119: 260-270, 2012.
31. Brain SD and Williams TJ: Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol 86: 855-860, 1985.